Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 439

Results For "MED"

7026 News Found

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
Digitisation | August 28, 2022

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes


Benvic acquires specialty U.S. compounder Chemres
News | August 27, 2022

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018


Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Drug Approval | August 27, 2022

Lupin receives UK MHRA Approval of Lutio for treatment of COPD

Lutio has the potential to offer significant cost savings when available to UK patients.


ENTOD organising nationwide campaign to encourage people to donate eyes
News | August 26, 2022

ENTOD organising nationwide campaign to encourage people to donate eyes

The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause


US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
News | August 26, 2022

US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad

The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.


10th Merck Bioforum India 2022 on Sept. 6-8
News | August 26, 2022

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape


Pristyn Care witnesses industry highest adoption of EMR
Healthcare | August 26, 2022

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim
News | August 25, 2022

Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

The cash consideration for the above acquisition will be Euro 26 million.